問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
李明璟
下載
2020-01-01 - 2029-12-31
Condition/Disease
Esophageal Squamous Cell Carcinoma (ESCC)、 Gastroesophageal Junction Carcinoma (GEJC)、 Esophageal Adenocarcinoma (EAC)
Test Drug
Pembrolizumab (MK-3475) KEYTRUDA®
Participate Sites7Sites
Not yet recruiting1Sites
Recruiting6Sites
2023-08-01 - 2027-04-01
Participate Sites3Sites
Recruiting3Sites
2020-06-01 - 2026-12-31
Hepatocellular Carcinoma (HCC)
注射液
Participate Sites4Sites
Recruiting4Sites
2023-12-01 - 2030-12-31
Not yet recruiting3Sites
Recruiting1Sites
全部
